Takeda Pharmaceutical Co. Ltd. ADR (TAK) News
Filter TAK News Items
TAK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TAK News Highlights
- TAK's 30 day story count now stands at 9.
- Over the past 17 days, the trend for TAK's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- TSE and STEM are the most mentioned tickers in articles about TAK.
Latest TAK News From Around the Web
Below are the latest news stories about TAKEDA PHARMACEUTICAL CO LTD that investors may wish to consider to help them evaluate TAK as an investment opportunity.
One Ultra-Cheap High-Yield Dividend Stock to BuyNow may be a good time for dividend investors to consider loading up on this stock. |
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior TherapiesOSAKA, Japan & CAMBRIDGE, Massachusetts, December 21, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarne |
Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of EmphysemaTakeda Canada Inc. (Takeda) has entered into a contract with Canadian Blood Services (CBS) for GLASSIA® (alpha-1 proteinase inhibitor) resulting from CBS's request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1). Glassia has been approved to be listed on the CBS Plasma Protein and Related Products (PPRP) formulary with specific criteria for reimbursement. This marks Takeda's entry into the Alpha-1 community in Canada, building on the company's commitment to dev |
13 Most Promising Healthcare Stocks According to AnalystsIn this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […] |
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)OSAKA, Japan & CAMBRIDGE, Mass., December 15, 2023--The CHMP has recommended the approval of Takeda's HYQVIA in patients with CIDP as maintenance therapy after stabilization with IVIG. |
30 Largest Pharmaceutical Companies in the WorldIn this article, we will be taking a look at the 30 largest pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 10 Largest Pharmaceutical Companies in the World. The world’s leading pharmaceutical companies became the center of attention for people all over the world as a […] |
20 Developed Countries in AsiaIn this article, we will look into the 20 developed countries in Asia. If you want to skip our detailed analysis, you can go directly to the 5 Developed Countries in Asia. Asia’s Economic Outlook Asia is a diverse region with some of its countries showing great economic potential. However, Asian countries must invest in […] |
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award WinnersOSAKA, Japan & CAMBRIDGE, Mass., December 05, 2023--Takeda (TSE:4502/NYSE:TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each winner receives an unrestricted prize of USD 200,000. |
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic DiseasesOSAKA, Japan & CAMBRIDGE, Mass., November 27, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that it will present 17 company-sponsored abstracts at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego. Takeda’s latest research focuses on improving treatment options for those living with hematologic diseases. |